Late last year we wrote about psychedelic stocks here Psychedelic Therapeutics. Here is quick update in the sector, of the five most advanced companies pursuing therapies.
ATAI is entering phase 3 clinical trials for lead drug candidate BLP-003 for TRD in 2026.
GHRS is also tackling TRD with an inhalant device, and will be entering phase 3 clinical trials in 2026. Both companies are utilizing psychedelic mebufotenin for TRD.
CMPS is preparing for NDA filing with COMP360 for TRD through FDA discussions. They are also advancing COMP360 for PTSD, with phase 3 studies scheduled in 2026.
DFTX, is using LSD for GAD and MDD, with MDD readout of the EMERGE study late second quarter. They have BTD for GAD. GAD is their primary program. DT120 had an effect on MDD also, in their phase 2 study.
HELP is the only adjunctive for MDD, with concomitant allowed,
in their phase 3 clinical trials. Their first phase 3 read-out for trial APPROACH is anticipated for the 4th quarter of 2026.
DXFT’s MDD readout, anticipated by the end of the second
quarter is the next catalyst for the sector.
A chart below of the five companies and their stock performance year to date. NOTE: All psychedelic stocks are much higher today, on the newly released executive order to expedite research into the mental health sector.
No comments:
Post a Comment